What is Kypha?
Kypha operates at the intersection of biotechnology and clinical diagnostics, specializing in the development of sophisticated biomarker testing platforms. The company's core technology provides real-time, precise data on complement and other critical proteins, which are essential for informing rapid and accurate treatment decisions. By offering a comprehensive suite of services—including assay development, custom panel creation, and exploratory biomarker analysis—Kypha enables healthcare providers to navigate complex immune-related conditions with greater clarity. Their commitment to regulatory compliance and multiplex analysis positions them as a vital partner for both therapeutic developers and clinical practitioners seeking to improve patient outcomes through data-driven insights.
How much funding has Kypha raised?
Kypha has raised a total of $6.9M across 3 funding rounds:
Private Equity
$750K
Debt
$2.1M
Series A
$4M
Private Equity (2013): $750K, investors not publicly disclosed
Debt (2015): $2.1M, investors not publicly disclosed
Series A (2018): $4M, investors not publicly disclosed
Key Investors in Kypha
Undisclosed Investor
An institutional capital partner focused on long-term growth and strategic development within the healthcare technology sector.
Undisclosed Investor
A financial institution specializing in structured debt solutions for high-growth biotechnology and diagnostic firms.
Undisclosed Investor
A venture firm dedicated to supporting early-to-mid-stage companies that are disrupting traditional clinical diagnostic methodologies.
What's next for Kypha?
With the successful closure of this major enterprise-level funding round, Kypha is poised to transition into a phase of aggressive operational scaling and technological refinement. The strategic roadmap likely involves the commercialization of its multiplex analysis platforms and the deepening of its research partnerships within the pharmaceutical industry. As the company continues to integrate its biomarker solutions into standard clinical workflows, the focus will shift toward enhancing the scalability of its assay development services. This growth phase is critical for Kypha as it seeks to establish its immune-monitoring technology as a gold standard in the diagnostic landscape, ultimately driving higher precision in therapeutic interventions and long-term clinical care.
See full Kypha company page
